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ABSTRACT
Introduction: In Australia, there is an unmet
need for improved treatments for rheumatoid
arthritis (RA). Tofacitinib is an oral Janus kinase
inhibitor for the treatment of RA. To provide an
overview of key study outcomes for tofacitinib
in Australian patients, we analyzed the efficacy
and safety of tofacitinib in the Australian sub-
population of global RA phase III and long-term
extension (LTE) studies.
Methods: Data were pooled from the Australian
subpopulation of four phase III studies and one
LTE study (database not locked at cut-off date:
January 2016). Patients in the phase III studies
received tofacitinib 5 or 10 mg twice daily (BID),
placebo (advancing to tofacitinib at months 3
or 6), or adalimumab, with background
methotrexate or conventional synthetic dis-
ease-modifying antirheumatic drugs. Patients in
the LTE study received tofacitinib 5 or 10 mg
BID. Efficacy endpoints were American College
of Rheumatology (ACR) 20/50/70 response
rates, and change from baseline in the Disease
Activity Score in 28 joints, erythrocyte sedi-
mentation rate [DAS28-4(ESR)] and Health
Assessment Questionnaire-Disability Index
(HAQ-DI) scores. Safety endpoints included
incidence of adverse events (AEs), serious AEs,
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and discontinuations due to AEs. AEs of special
interest and laboratory parameters were ana-
lyzed in the LTE study.
Results: Across phase III studies (N = 100), ACR
response rates and improvements in DAS28-
4(ESR) and HAQ-DI scores were numerically
greater with tofacitinib vs. placebo at month 3,
and increased until month 12. The results were
sustained in the LTE study (N = 99) after
60 months’ observation. In general, the efficacy
and safety profiles of tofacitinib were similar to
those of the global RA population.
Conclusions: In Australian patients with RA,
tofacitinib therapy demonstrated sustained effi-
cacy and consistent safety over C 60 months’
treatment.
Funding: Pfizer Inc.
Trial registration numbers (all ClinicalTri-
als.gov): NCT00960440; NCT00847613;
NCT00856544; NCT00853385; NCT00413699.
Keywords: Australia; Efficacy; Rheumatoid
arthritis; Safety; Tofacitinib
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disease characterized by persistent
joint synovial tissue inflammation [1]. Uncon-
trolled RA is associated with reduced health-
related quality of life (HRQoL) [2] and prema-
ture mortality [3, 4], and results in a substantial
burden in terms of cost, disability, and loss of
productivity [5]. Previous reports have esti-
mated the prevalence of RA to be 0.6% in
Australia [6] and 0.5% in Australasia [7]; these
are slightly higher than prevalence estimates for
Western Europe (0.4%), North America (0.4%),
and Southeast Asia (0.2%) [7].
There also appears to be a considerable
unmet need for improved disease control for
patients with RA in Australia. The treat-to-target
approach for RA aims to achieve clinical remis-
sion or low disease activity (LDA) and to main-
tain physical functioning and good quality of
life [8]. Early treatment with disease-modifying
antirheumatic drugs (DMARDs) is the recom-
mended best-practice approach to disease
management [8–11]. However, two studies of
prescribing patterns in RA patients in Australian
community-based practice have shown that
disease activity remains inadequately controlled
in a large proportion of patients, despite treat-
ment with conventional synthetic DMARDS
(csDMARDs) or biological DMARDS
(bDMARDs); it was reported that over 39% [12]
and 47% [13] of patients receiving treatment for
RA still experienced moderate to high disease
activity. Treatment preference studies among
patients with RA have shown that patients favor
oral medications compared with subcutaneous
(SC) self-injection and intravenous infusion
[14, 15]; patient adherence and, consequently,
treatment outcomes may be improved through
the use of oral medications as opposed to SC or
intravenous alternatives.
Tofacitinib is an oral Janus kinase inhibitor
for the treatment of RA. The efficacy and safety
of tofacitinib 5 and 10 mg twice daily (BID),
administered as monotherapy or in combina-
tion with csDMARDs [mainly methotrexate
(MTX)], in patients with moderately to severely
active RA, have been demonstrated in phase II
[16–20] and phase III [21–26] randomized con-
trolled trials of up to 24 months’ duration, and
in long-term extension (LTE) studies with up to
114 months of observation [27–29]. Tofacitinib
was not available in Australia at the time of the
two Australian real-world studies discussed
above; however, it is now available for the
treatment of the signs and symptoms of
moderate-to-severe RA in adults who have had
an inadequate response (IR) or are intolerant to
MTX [30]. Tofacitinib may be used alone or in
combination with csDMARDs, including MTX,
at a recommended dose of 5 mg BID.
Broadening our clinical understanding of
treatments for RA in patients from Australia
may improve the number of patients able to
achieve remission or LDA. To provide an over-
view of key study outcomes for tofacitinib in
Australian subjects, we pooled the efficacy and
safety data for tofacitinib 5 and 10 mg BID in
the Australian subpopulation of the tofacitinib
RA global phase III studies in csDMARD- or
bDMARD-IR patients, and an LTE study
including csDMARD-IR, bDMARD-IR, and MTX-
naı¨ve patients.
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METHODS
Patients
The efficacy and safety data included in these
post hoc analyses were from the Australian
subpopulation of four global tofacitinib RA
phase III studies [ORAL Step (NCT00960440)
[21]; ORAL Scan (NCT00847613) [25]; Oral Sync
(NCT00856544) [23]; and ORAL Standard
(NCT00853385) [26]] and one LTE study [ORAL
Sequel (NCT00413699) [28]]. Full details of
these studies, including patient inclusion and
exclusion criteria, have been reported
previously.
Eligible patients were aged C 18 years with
moderately to severely active RA, based on the
American College of Rheumatology (ACR) 1987
revised criteria. Patients enrolled in the phase III
studies in this analysis had an IR to MTX (ORAL
Scan, ORAL Standard), csDMARDs or bDMARDs
(ORAL Sync), or tumor necrosis factor inhibitor
therapy (ORAL Step). Patients enrolled in the
LTE study had previously participated in a
qualifying phase I, II, or III index study of
tofacitinib. In the Australian subpopulation,
patients entered the LTE from phase III studies
only (phase I and II studies were not conducted
in Australia), including those mentioned above,
as well as ORAL Start, which included patients
naı¨ve to therapeutic doses of MTX [24].
Studies
The four phase III studies included in these
analyses were randomized, double-blind,
placebo-controlled clinical trials of C 6 months’
duration [21, 23, 25, 26]. Patients were ran-
domized to receive tofacitinib 5 or 10 mg BID or
placebo with background MTX (ORAL Step,
ORAL Scan, and ORAL Standard) or csDMARDs
(ORAL Sync). ORAL Standard included an active
control arm of adalimumab 40 mg SC every
other week (Q2W) in patients receiving back-
ground MTX. In studies of C 6 months’ dura-
tion (ORAL Scan, ORAL Sync, and ORAL
Standard), patients receiving placebo were
advanced to tofacitinib 5 or 10 mg BID at
month 3 (non-responding patients; patients
who did not achieve C 20% reduction from
baseline in swollen and tender joint counts) or
month 6 (all remaining placebo-treated
patients). In ORAL Step (6 months’ duration),
all placebo patients were advanced to
tofacitinib 5 or 10 mg BID at month 3 on a
blinded basis.
All Australian patients commenced treat-
ment in the open-label LTE study with
tofacitinib 10 mg BID as monotherapy, or with
background csDMARDs, according to their
index study [28]. Doses of tofacitinib (5 or
10 mg BID) or background medication in the
LTE study could be adjusted according to the
investigators’ assessment of efficacy and safety.
All studies included in these analyses were
conducted in compliance with the Declaration
of Helsinki and the Good Clinical Practice
Guidelines of the International Conference
on Harmonisation, and were approved by the
relevant Institutional Review Board and/or
Independent Ethics Committee of the investi-
gational centers. All patients provided written,
informed consent.
Analysis Populations
Two datasets were included in the analysis: one
for the phase III studies, which included up to
12 months of efficacy and safety data for
Australian patients pooled from four phase III
studies (ORAL Step, ORAL Scan, ORAL Sync,
and ORAL Standard), and one for the LTE study,
which included data for all Australian patients
treated in ORAL Sequel.
The LTE study was ongoing at the time of
analysis; data collection and analyses were
continuing, and the study database was not yet
locked (i.e., some values may change for the
final, locked study database). LTE efficacy and
safety data were included through 60 and
69 months of observation, respectively (data
cut-off: January 14, 2016).
Efficacy and Safety Analysis
Efficacy was assessed every 3 months until
month 12 in the phase III studies, and every
6 months until month 60 in the LTE study. The
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efficacy endpoints for both the phase III and
LTE datasets included the proportions of
patients achieving ACR20, ACR50, or ACR70
responses (defined as an improvement from
baseline of at least 20, 50, and 70%, respec-
tively, in the number of tender and swollen
joints and at least three of the five ACR com-
ponents), and improvements from baseline in
the Disease Activity Score in 28 joints using
erythrocyte sedimentation rate [DAS28-4(ESR)]
and Health Assessment Questionnaire-Disabil-
ity Index (HAQ-DI). The proportions of patients
achieving remission and LDA [DAS28-4(ESR)
\2.6 and B 3.2, respectively) [31] were evalu-
ated in the pooled phase III dataset, along with
patient-reported outcomes. These included
HRQoL evaluated using the Medical Outcomes
Study Short Form-36 Health Survey [SF-36;
including eight domains summarized into a
physical component summary (PCS) score and a
mental component summary (MCS) score],
patient global assessment of disease activity
(PtGA) recorded using a visual analog scale
(VAS), patient global assessment of arthritis
pain assessed utilizing a VAS, fatigue assessed
using the Functional Assessment of Chronic
Illness Therapy-Fatigue (FACIT-F), and sleep
disturbance assessed using the Medical Out-
comes Study sleep scale. The proportion of
patients who achieved improvements greater
than the minimum clinically important differ-
ence (MCID) in PtGA (10 points) [32], pain (10
points) [32], SF-36 PCS and MCS (2.5 points)
[32, 33], and FACIT-F (4 points) [34] were also
determined.
The safety analyses for both the pooled phase
III dataset and the LTE study included the
incidence of adverse events (AEs), serious AEs
(SAEs), and discontinuations due to AEs. Addi-
tionally, several AEs of special interest were
analyzed in the LTE study, including serious
infection events (SIEs), all herpes zoster (HZ)
events (serious and non-serious), non-
melanoma skin cancer (NMSC), all malignan-
cies (excluding NMSC), melanoma, oppor-
tunistic infections [excluding tuberculosis (TB)],
and major adverse cardiovascular events. The
laboratory parameters analyzed for the LTE
study were hemoglobin, absolute lymphocyte
count (ALC), absolute neutrophil count (ANC),
creatinine, high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) cholesterol,
alanine aminotransferase (ALT), and aspartate
aminotransferase (AST).
Statistical Analysis
All analyses were based on observed cases of the
full analysis set, which included all patients
who were randomized and received at least one
dose of study treatment (tofacitinib, placebo, or
adalimumab).
In the pooled phase III data analyses, the
data are presented according to the study
treatment received. The placebo groups in the
phase III studies were combined up to month 3,
irrespective of the tofacitinib dose to which
they were advanced. Numerical comparisons
were made between the tofacitinib-treated and
placebo-treated populations through month 3,
prior to advancement of the placebo group to
tofacitinib.
For the LTE data analyses, the baseline was
defined as that of the qualifying index study for
patients who enrolled in the LTE study within
14 days of the final visit of the index study. If
enrollment was[ 14 days after participation in
the index study, the baseline was taken as the
start of the LTE study. Assignment to the
tofacitinib 5 or 10 mg BID group in the LTE
analysis was based on the calculation of the
average total daily dose (TDD; sum of all doses
received divided by the number of days of
treatment) for each patient. Patients with
TDD\15 mg were assigned to the 5 mg BID
group, while patients with TDD C 15 mg were
assigned to the 10 mg BID group.
All analyses were descriptive in nature. As the
studies were not powered to detect differences
between treatment groups in this population, no
statistical testing was performed.
RESULTS
Patients
Across the phase III studies, 100 Australian
patients with RA were randomized to receive
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tofacitinib 5 mg BID (n = 33), tofacitinib 10 mg
BID (n = 47), placebo (n = 13), or adalimumab
40 mg Q2W (n = 7). The demographic and
baseline disease characteristics are reported in
Table 1. The majority of patients in the
Australian population were female, with
Table 1 Baseline demographics and disease characteristics of the Australian subpopulation (phase III and LTE studies)
Phase III studies (N = 100) LTE study (N = 99)
Tofacitinib
5 mg BID
(N = 33)
Tofacitinib
10 mg BID
(N = 47)
Placebo
(N = 13)
Adalimumab
40 mg Q2W
(N = 7)
Tofacitinib
5 mg BID
(N = 2)
Tofacitinib
10 mg BID
(N = 97)
Baseline demographics
Mean age (SD),
years
58.8 (10.9) 54.3 (10.7) 51.3 (15.3) 56.7 (11.3) 55.5 (2.1) 56.6 (12.0)
Female, n (%) 21 (63.6) 34 (72.3) 9 (69.2) 6 (85.7) 1 (50.0) 62 (63.9)
Race, n (%)
White 30 (90.9) 44 (93.6) 13 (100.0) 6 (85.7) 2 (100.0) 91 (93.8)
Asian 1 (3.0) 2 (4.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.1)
Other 2 (6.1) 1 (2.1) 0 (0.0) 1 (14.3) 0 (0.0) 4 (4.1)
Baseline disease characteristics
Mean RA disease
duration
(range), years
12.1 (0.4–38.0) 9.0 (0.3–30.0) 9.0 (0.3–26.0) 6.2 (0.3–13.0)
RF positive,
n (%)
21 (63.6) 27 (58.7) 7 (53.8) 6 (85.7)
Anti-CCP
positive, n (%)
22 (66.7) 26 (56.5)a 8 (61.5) 6 (100.0)a
Mean TJC (SD) 26.4 (16.3) 25.1 (16.2) 26.9 (18.0) 28.6 (13.5)
Mean SJC (SD) 18.4 (10.4) 14.5 (6.8) 20.2 (11.6) 18.0 (8.3)
Mean DAS28-
4(ESR) (SD)
6.0 (1.3) 5.9 (1.1) 5.9 (1.2) 6.0 (0.9) 5.2 (1.0) 5.8 (1.1)
Mean HAQ-DI
(SD)
1.2 (0.8) 1.1 (0.7) 1.2 (1.0) 1.7 (0.6) 0.9 (0.6) 1.2 (0.8)
Mean CRP (SD),
mg/l
12.8 (10.8) 14.4 (17.3) 10.4 (7.5) 13.2 (15.9)
Mean ESR (SD),
mm/h)
38.6 (23.9) 42.6 (23.1) 38.2 (24.1) 55.7 (19.5)
BID twice daily, CCP cyclic citrullinated peptide antibody, CRP C-reactive protein, DAS28-4(ESR) Disease Activity Score
in 28 joints, erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, LTE long-term
extension, Q2W every other week, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SJC swollen joint
count, TJC tender joint count
a For anti-CCP positive, N = 46 for tofacitinib 10 mg BID and N = 6 for adalimumab 40 mg Q2W
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established RA (mean disease duration[6 years
in all treatment groups) and a high level of
baseline disease activity [mean DAS28-4(ESR)
C 5.9 in all treatment groups]. The majority of
patients in each treatment group were Cau-
casian (C 85.7%). Patients in the tofacitinib
5 mg BID group had the longest mean disease
duration (12.1 years); this was almost twice that
of patients in the adalimumab group, though
the smaller sample size must be taken into
consideration.
The LTE study involved 99 Australian
patients, with tofacitinib exposure of
322.5 patient-years. Two patients received an
average TDD of tofacitinib 5 mg BID; one dis-
continued treatment after month 3 due to
insufficient clinical response. Data from the LTE
study for patients receiving tofacitinib 5 and
10 mg BID are presented together in these
analyses, unless otherwise indicated.
Efficacy
In the phase III studies, patients receiving
tofacitinib 5 and 10 mg BID had numerically
greater ACR20 response rates than those
receiving placebo at months 1 and 3; ACR20
response rates increased to month 12 (Fig. 1a).
The ACR50 response rates in the treatment
groups also improved over time to month 12
(Fig. 1b). ACR70 response rates were either zero
or low for all groups prior to month 3, and
increased over time until month 12 (Fig. 1c). By
month 12, all placebo-treated patients had
advanced to tofacitinib and achieved ACR20,
ACR50, and ACR70 response rates similar to
those of the tofacitinib-treated patients.
At month 12, a numerically higher propor-
tion of patients who had received placebo and
advanced to tofacitinib achieved clinical
remission [DAS28-4(ESR)\ 2.6] and LDA
[DAS28-4(ESR) B 3.2], compared with
tofacitinib-treated patients (Fig. 1d). Treatment
with tofacitinib 5 and 10 mg BID was associated
with numerically greater improvement vs. pla-
cebo in DAS28-4(ESR) scores at months 1 and 3
(Fig. 1e); however, it must be noted that not all
patients had DAS28-4(ESR) scores assessed at
month 1. The mean changes from baseline in
DAS28-4(ESR) were similar for all groups at
months 6 and 12, including the placebo-treated
patients, once they had been advanced to
tofacitinib; the numerically higher rates of
remission and LDA in these patients may be due
to low patient numbers compared with tofaci-
tinib-treated patients.
HAQ-DI scores decreased from baseline
through month 12, indicating improvement
with active treatment (Fig. 1f). After month 6,
improvement in HAQ-DI was also observed in
patients who had advanced from placebo to
tofacitinib.
Adalimumab resulted in similar ACR20 and
lower ACR50 response rates vs. tofacitinib at
Month 12; none of the seven patients receiving
adalimumab achieved an ACR70 response
(Fig. 1a–c). Additionally, although similar
changes from baseline in DAS28-4(ESR) and
HAQ-DI were observed with tofacitinib and
adalimumab at month 12 (Fig. 1e–f), a numeri-
cally lower percentage of adalimumab-treated
patients achieved remission and LDA vs.
patients receiving tofacitinib (Fig. 1d).
Efficacy improvements with tofacitinib were
sustained for up to 60 months of treatment in
the LTE study (Fig. S1). In tofacitinib-treated
patients, ACR response rates generally increased
between month 1 and 60 (Fig. S1a). Mean
improvements from baseline in DAS28-4(ESR)
scores remained stable through month 60 in
patients receiving tofacitinib (Fig. S1b). Mean
HAQ-DI scores also improved from baseline,
although a slight decrease in the change from
bFig. 1 Efficacy over time in the pooled phase III study
population, as measured by a ACR20 response rates,
b ACR50 response rates, c ACR70 response rates,
d proportion of patients achieving clinical remission and
LDA at month 12, as measured by DAS28-4(ESR), e mean
change from baseline in DAS28-4(ESR), and f mean
change from baseline in HAQ-DI (FAS, no imputation).
Remission was defined as DAS28-4(ESR)\ 2.6. LDA was
defined as DAS28-4(ESR) B 3.2. ACR American College
of Rheumatology, BID twice daily, DAS28-4(ESR) Disease
Activity Score in 28 joints, erythrocyte sedimentation rate,
FAS full analysis set, HAQ-DI Health Assessment Ques-
tionnaire-Disability Index, LDA low disease activity, Q2W
every other week, SE standard error
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baseline was observed at months 48 and 54
before increasing again at month 60 (Fig. S1c).
Analysis of PROs in the phase III Australian
subpopulation showed that treatment with
tofacitinib 5 and 10 mg BID improved SF-36
scores, PtGA, pain, fatigue, and sleep distur-
bance. Consistent increases from baseline,
indicating improvement, were seen in all eight
domains of the SF-36 at month 3 with
tofacitinib 5 and 10 mg BID (Fig. 2a). SF-36
mean PCS and MCS improved from baseline to
month 12 in patients treated with tofacitinib 5
and 10 mg BID (Fig. 2b–c). There was a slight
increase in PCS and MCS at month 1 in patients
receiving placebo, but this was not sustained to
month 3. Improvements from baseline PCS and
MCS were observed at month 6 after patients
switched from placebo to tofacitinib at either
month 3 or 6. Patients receiving adalimumab
achieved greater changes from baseline in SF-36
social function, vitality, bodily pain, and gen-
eral health domains at month 3, and similar
changes from baseline in PCS and MCS scores at
month 12 compared with patients receiving
tofacitinib (Fig. 2).
In the tofacitinib 5 and 10 mg BID treatment
groups, improvements in PtGA, pain, fatigue,
and sleep disturbance scores were observed until
month 12 (Figs. S2a–d). Similar improvements
were observed in the placebo-treated patients
after month 6 upon advancement to tofacitinib.
The seven patients receiving adalimumab
appeared to experience similar improvements
from baseline compared with tofacitinib
through month 12 in all PROs except PtGA
(Figs. S2a–d).
Furthermore, patients receiving tofacitinib
5 or 10 mg BID were more likely to achieve
clinically meaningful improvements for PtGA,
pain, SF-36 PCS, and FACIT-F at month 1 and 3
(Table S1) vs. patients receiving placebo, as
more patients reported improvements that were
greater than the MCID.
Safety
During months 0–3 of the phase III studies, the
incidence of AEs was similar between the
tofacitinib and placebo groups. The incidence
of AEs in patients receiving tofacitinib 5 and
10 mg BID was 78.8 and 72.3%, respectively, at
months 0–3, 51.4 and 48.1%, respectively, at
months 3–6, and 55.9 and 46.3%, respectively,
post-month 6 (Table 2). SAEs and discontinua-
tions due to AEs occurred more frequently with
tofacitinib vs. placebo until month 6 (Table 2).
Of the seven adalimumab-treated
patients, four reported AEs at months 0–3, two
at months 3–6, and two post-month 6. One
patient reported an SAE at months 3–6. None of
the patients receiving adalimumab discontin-
ued due to AEs during the phase 3 studies
(Table 2).
During the LTE study, SAEs were reported in
50 (50.5%) tofacitinib-treated patients (Table 2).
Overall, 53 (53.5%) patients discontinued the
study; 27 discontinued due to study drug-related
AEs, while eight discontinued due to insufficient
clinical response, including one patient receiving
tofacitinib 5 mg BID (data not shown).
Upper respiratory tract infection was the
most frequently occurring AE in patients
receiving tofacitinib 5 and 10 mg BID during
months 0–3 (12.1 and 8.5%, respectively),
months 3–6 (5.4 and 9.3%, respectively), and
post-month 6 (8.8 and 18.5%, respectively) of
the phase III studies (Table 3). Upper respiratory
tract infection was also the most commonly
reported treatment-emergent AE during the LTE
study (45.5%) (Table 3).
The AEs of special interest reported during
the LTE study are listed in Table 3. The most
common AE of special interest was NMSC, fol-
lowed by SIEs; these were reported in 22 [inci-
dence rate: 7.8 (95% confidence interval (CI)
4.9, 11.9)] and 21 [incidence rate: 6.6 (95% CI
4.1, 10.0)] patients, respectively. HZ occurred in
18 (18.2%) patients; three cases were serious
and patients permanently discontinued treat-
ment, and all except one non-serious case were
resolved. Malignancies and opportunistic
infections were each reported in four (4.0%)
patients during the LTE study (Table 3).
Laboratory Parameters
Selected laboratory parameters assessed during
the LTE study are summarized in Fig. 3 and
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Table S2. Hemoglobin levels slightly decreased
from baseline to month 30 with tofacitinib
treatment, subsequently increased to month 48,
then decreased to month 60 (Fig. 3a). Mean ALC
decreased through month 60 (Fig. 3b). The
mean ANC somewhat decreased at month 1 and
fluctuated throughout the LTE study, but by
month 60 had returned to a similar level as
month 1 (Fig. 3c). Mean creatinine levels
increased from baseline at month 1, and also
fluctuated before returning to a level similar to
month 1 by month 60 (Fig. 3d). HDL
cholesterol levels increased from baseline at
month 1 and remained stable, but LDL choles-
terol levels initially increased to month 24,
decreased at month 30, then increased at
month 36 before decreasing to below the base-
line value at month 60 (Fig. 3e). A summary of
abnormal laboratory observations meeting pro-
tocol for monitoring or discontinuation is pro-
vided in Table S2. The proportions of patients
receiving tofacitinib who had confirmed
decreases in hemoglobin, neutrophil count, and
lymphocyte count, and increases in AST and/or
Fig. 2 PROs in the pooled phase III study population
showing the mean changes from baseline a across eight SF-
36 domain scores at month 3, b in SF-36 PCS to month
12, and c in SF-36 MCS to month 12 (FAS, no
imputation). BID twice daily, FAS full analysis set, MCS
mental component summary, PCS physical component
summary, PROs patient-reported outcomes, Q2W every
other week, SE standard error, SF-36 Short Form-36
Health Survey
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ALT levels, and serum creatinine, was B 5.1%
for each measurement.
DISCUSSION
These post hoc analyses demonstrated the effi-
cacy and safety of tofacitinib 5 and 10 mg BID
in combination with MTX or csDMARDs in
reducing signs and symptoms of RA and
improving physical function in the Australian
subpopulation of patients participating in the
global tofacitinib RA development program.
Across phase III studies, ACR response rates
and improvements in mean DAS28-4(ESR) and
mean HAQ-DI were observed at month 1 and
continued to increase throughout 12 months’
Table 2 Summary of AEs, discontinuations due to AEs, SAEs, and AEs of special interest during the phase III studies and
the LTE
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID
Placebo Adalimumab
40 mg Q2W
Months 0–3
Subjects evaluable for AEs, N 33 47 13 7
Subjects with AEs, n (%) 26 (78.8) 34 (72.3) 10 (76.9) 4 (57.1)
Subjects with SAEs, n (%) 2 (6.1) 3 (6.4) 0 (0.0) 0 (0.0)
Discontinuations due to AEs, n (%) 1 (3.0) 1 (2.1) 0 (0.0) 0 (0.0)
Months 3–6a
Subjects evaluable for AEs, N 37 54 2 7
Subjects with AEs, n (%) 19 (51.4) 26 (48.1) 2 (100.0) 2 (28.6)
Subjects with SAEs, n (%) 4 (10.8) 1 (1.9) 0 (0.0) 1 (14.3)
Discontinuations due to AEs, n (%) 3 (8.1) 2 (3.7) 0 (0.0) 0 (0.0)
Post-month 6a
Subjects evaluable for AEs, N 34 54 0 7
Subjects with AEs, n (%) 19 (55.9) 25 (46.3) N/A 2 (28.6)
Subjects with SAEs, n (%) 1 (2.9) 5 (9.3) N/A 0 (0.0)
Discontinuations due to AEs, n (%) 0 (0.0) 2 (3.7) N/A 0 (0.0)
LTE studyb
Subjects evaluable for AEs, N 99
Subjects with AEs, n (%) 96 (97.0)
Subjects with SAEs, n (%) 50 (50.5)
Discontinuations due to AEs, n (%) 33 (33.3)
AE adverse event, BID twice daily, LTE long-term extension, N/A not applicable, Q2W every other week, SAE serious
adverse event, TDD total daily dose
a Tofacitinib groups included patients initially receiving placebo who had advanced at month 3 or month 6
b Includes patients receiving a TDD of tofacitinib 5 mg BID (n = 2) and 10 mg BID (n = 97). One patient receiving
tofacitinib 5 mg BID discontinued treatment after month 3
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Table 3 Summary of the most commonly reported AEs (C 5% in any tofacitinib group) during the phase III studies and
the LTE study, and AEs of special interest during the LTE study
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID
Placebo Adalimumab
40 mg Q2W
Months 0–3, n (%) (N = 33) (N = 47) (N = 13) (N = 7)
Upper respiratory tract infection 4 (12.1) 4 (8.5) 0 (0.0) 1 (14.3)
Urinary tract infection 3 (9.1) 1 (2.1) 1 (7.7) 1 (14.3)
Nausea 2 (6.1) 3 (6.4) 1 (7.7) 0 (0.0)
Diarrhea 2 (6.1) 1 (2.1) 2 (15.4) 0 (0.0)
Back pain 2 (6.1) 1 (2.1) 0 (0.0) 0 (0.0)
Headache 2 (6.1) 0 (0.0) 2 (15.4) 0 (0.0)
Mouth ulceration 2 (6.1) 0 (0.0) 1 (7.7) 0 (0.0)
Lower respiratory tract infection 1 (3.0) 4 (8.5) 0 (0.0) 0 (0.0)
Incorrect dose administered 0 (0.0) 4 (8.5) 1 (7.7) 0 (0.0)
Rash 0 (0.0) 3 (6.4) 0 (0.0) 0 (0.0)
Months 3–6,a n (%) (N = 37) (N = 54) (N = 2) (N = 7)
Upper respiratory tract infection 2 (5.4) 5 (9.3) 0 (0.0) 0 (0.0)
Urinary tract infection 3 (8.1) 3 (5.6) 0 (0.0) 1 (14.3)
Fall 2 (5.4) 2 (3.7) 0 (0.0) 0 (0.0)
Arthralgia 2 (5.4) 1 (1.9) 0 (0.0) 0 (0.0)
Back pain 2 (5.4) 0 (0.0) 1 (50.0) 0 (0.0)
Rash 2 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 0 (0.0) 3 (5.6) 0 (0.0) 0 (0.0)
Vomiting 0 (0.0) 3 (5.6) 0 (0.0) 0 (0.0)
Post-month 6,a n (%) (N = 34) (N = 54) (N = 0) (N = 7)
Upper respiratory tract infection 3 (8.8) 10 (18.5) N/A 1 (14.3)
Lower respiratory tract infection 2 (5.9) 6 (11.1) N/A 0 (0.0)
Sinusitis 4 (11.8) 0 (0.0) N/A 0 (0.0)
Hypertension 2 (5.9) 2 (3.7) N/A 0 (0.0)
Fall 2 (5.9) 2 (3.7) N/A 0 (0.0)
Pneumonia 2 (5.9) 1 (1.9) N/A 0 (0.0)
Atypical fibroxanthoma 2 (5.9) 0 (0.0) N/A 0 (0.0)
Cataract 2 (5.9) 0 (0.0) N/A 0 (0.0)
Tinea pedis 2 (5.9) 0 (0.0) N/A 0 (0.0)
Urinary tract infection 1 (2.9) 3 (5.6) N/A 0 (0.0)
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Table 3 continued
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID
Placebo Adalimumab
40 mg Q2W
LTE study,b n (%) (N = 99)
Upper respiratory tract infection 45 (45.5)
Lower respiratory tract infection 22 (22.2)
Urinary tract infection 19 (19.2)
HZc 18 (18.2)
Basal cell carcinoma 13 (13.1)
Fall 12 (12.1)
Pneumonia 11 (11.1)
Arthralgia 10 (10.1)
Actinic keratosis 10 (10.1)
Skin lesion 10 (10.1)
Diarrhea 9 (9.1)
Squamous cell carcinoma 9 (9.1)
Nausea 8 (8.1)
Gastroenteritis 8 (8.1)
Pain in extremity 8 (8.1)
Back pain 8 (8.1)
Vitamin D deficiency 7 (7.1)
Laceration 7 (7.1)
Bursitis 7 (7.1)
Bowen’s disease 7 (7.1)
Rash 7 (7.1)
Hypertension 7 (7.1)
Respiratory tract infection 6 (6.1)
Neck pain 6 (6.1)
Anemia 5 (5.1)
Cataract 5 (5.1)
Gastroesophageal reflux disease 5 (5.1)
Bronchitis 5 (5.1)
Tooth abscess 5 (5.1)
Skin papilloma 5 (5.1)
Influenza 5 (5.1)
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treatment with tofacitinib. These efficacy
improvements with tofacitinib were maintained
during the LTE study (up to 60 months’ treat-
ment); however, it must be noted that patient
numbers decreased throughout the LTE study
due to discontinuations of treatment, or as
some patients had not yet reached the later
assessment time points by the time of the data
cut for this analysis.
Table 3 continued
Tofacitinib
5 mg BID
Tofacitinib
10 mg BID
Placebo Adalimumab
40 mg Q2W
Osteoarthritis 5 (5.1)
Musculoskeletal pain 5 (5.1)
Sciatica 5 (5.1)
AEs of special interest during the LTE studyb (N = 99)
Total patient-years of drug exposure: 322.5
Patients with events Incidence rate (95% CI)
NMSC 22 7.8 (4.9, 11.9)
SIE 21 6.6 (4.1, 10.0)
HZd 18 6.1 (3.6, 9.7)
Serious 3
Non-serious 15
OIs (excluding TB)e 4 1.2 (0.3, 3.2)
Varicella zoster virus infection 1
Cytomegaloviral pneumonia 1
Esophageal candidiasis 1
Cryptococcal pneumonia 1
Malignancies excluding NMSC 4 1.2 (0.3, 3.2)
Melanoma 2
Acute myeloid leukemia 1
Colorectal cancer 1
MACE 2 0.6 (0.1, 2.3)
AE adverse event, BID twice daily, CI confidence interval, HZ herpes zoster, LTE long-term extension, MACE major
adverse cardiovascular events, N/A not applicable, NMSC non-melanoma skin cancer, OI opportunistic infection, Q2W
every other week, SIE serious infection event, TB tuberculosis, TDD total daily dose
a Tofacitinib groups included patients initially receiving placebo who had advanced at months 3 or 6
b Includes patients receiving a TDD of tofacitinib 5 mg BID (n = 2) and tofacitinib 10 mg BID (n = 97). One patient
receiving tofacitinib 5 mg BID discontinued treatment after month 3
c Includes a collection of HZ terms
d All cases of HZ were resolved except one
e All cases of OI were resolved
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In general, the efficacy and safety profiles of
tofacitinib observed in the Australian subpopu-
lation were similar to those reported previously
for the global RA tofacitinib population
[21, 23, 25, 26, 29]. Australian patients had
numerically higher rates of ACR20 response and
DAS28-4(ESR)-defined remission than the glo-
bal population (inclusive of Australian patients)
in the phase III tofacitinib studies at month 6
[ACR20: 71.4 and 61.9% (Australian cohort) vs.
Fig. 3 Summary of changes in laboratory variables follow-
ing treatment with tofacitiniba during the LTE study,
showing mean change from baseline in a hemoglobin (g/dl),
b absolute lymphocyte count (109 cells/l), c absolute neu-
trophil count (109 cells/l), d serum creatinine (mg/dl), and
e HDL and LDL cholesterol (percent change). BID twice
daily, HDL high-density lipoprotein, LDL low-density
lipoprotein, LTE long-term extension, SE standard error,
TDD total daily dose
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51.1–52.1 and 52.6–61.8% (global phase III
studies); remission: 21.4 and 22.5% (Australian
cohort) vs. 6.2–10.7 and 12.5–16.0% (global
phase III studies) for tofacitinib 5 and 10 mg
BID, respectively] [21, 23, 25, 26].
Our analysis also suggested that treatment
with tofacitinib 5 and 10 mg BID reduced the
broad burden of active RA in the Australian
subpopulation of patients from the phase III RA
studies. Treatment with tofacitinib for
3 months resulted in clinically meaningful
improvements, indicated by the changes from
baseline greater than the MCID, across multiple
PROs, consistent with the primary efficacy
findings.
Tofacitinib demonstrated a consistent safety
profile in both the phase III and LTE studies,
with no new safety signals detected through
69 months’ observation in the LTE study. In the
LTE study, a higher percentage of Australian
patients experienced SAEs (50.5 vs. 29.4%) and
discontinued the study due to AEs (33.3 vs.
23.9%) compared with the combined global and
Japanese LTE population [29]. The differences in
the Australian population are unexplained;
however, the number of patient-years of expo-
sure for tofacitinib 10 mg BID in the Australian
subpopulation (322.5 patient-years) was\ 2%
of that of the global and Japanese LTE study
population (17,738.5 patient-years) [29], which
may account for the discrepancies in the results.
Additionally, incidence rates (95% CI) of NMSC
were higher in the tofacitinib-treated Australian
LTE subpopulation [7.8 (4.9, 11.9)] compared
with the tofacitinib-treated global LTE and glo-
bal phase I, II, III, and LTE populations [0.64
(0.50–0.81) and 0.55 (0.45–0.69), respectively]
[35]. This may also be due to the small numbers
of patients in the studies (99 vs. 4847 and 6092,
respectively); however, the high levels of sun
exposure in Australia may potentially con-
tribute to the higher rates of NMSC in this
population, as well as the high diagnosis rate for
such lesions in Australia [36, 37]. Furthermore,
the history of NMSC in these patients is not
known; the risk of developing NMSC is higher
in patients who have previously had NMSC
[38]. Further research is needed on the inci-
dence of NMSC in tofacitinib-treated patients in
populations with high sun exposure. Incidence
rates (95% CI) of HZ and opportunistic infec-
tions (excluding TB) were higher in the
Australian LTE subpopulation, compared with
an analysis of tofacitinib global phase I, II, III,
and LTE data [6.1 (3.6, 9.7) vs. 3.9 (3.6–4.2) and
1.2 (0.3, 3.2) vs. 0.3 (0.2–0.4), respectively] [39].
Finally, the mean overall values for laboratory
safety parameters in the Australian subpopula-
tion also demonstrated variability compared
with the global and Japanese populations, again
likely due to the limited number of patients.
Although the mean changes from baseline in
ANC were similar to those of the global phase III
and LTE population, the mean ALC in the
Australian subpopulation showed a greater
decrease from baseline compared with the glo-
bal population [40] and appeared to decrease
through month 60. This may also be a conse-
quence of the smaller number of patients in the
Australian subpopulation, as it is also in con-
trast to the larger global population, from
which a pooled analysis of six phase III RCTs
and two LTE studies indicated that lymphocyte
count decreases stabilized at approximately
month 48 [40]. Hemoglobin levels also
decreased in the Australian subpopulation; this
is in contrast to the global population, in which
hemoglobin levels generally tended to increase
[28, 40].
A general limitation of this study is that the
analyses were post hoc, and due to small sample
sizes and the short duration of exposure to
placebo or adalimumab in the phase III studies,
no statistical analyses were performed to com-
pare safety or efficacy between treatment
groups. Furthermore, there was no batch ran-
domization by country to ensure the even dis-
tribution of patients to each treatment group
within a country, which may have resulted in
an imbalance between treatment groups and
low numbers in some groups. Additionally, the
pooling of the data from four phase III studies
with different designs and methodology may
have led to a heterogeneous patient population.
Australia is an ethnically diverse country, which
overall has a Caucasian population of approxi-
mately 75% [41]; this should be taken into
account when considering the wider applica-
bility of these data from an analysis where
C 93% of all patients were Caucasian.
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LTE studies involve a highly selected patient
population who have successfully completed
the preceding index studies, and in whom the
study drug is known to be efficacious and well
tolerated. Thus, the design can overestimate
benefit and underestimate harm [28]. Another
drawback of such studies is that both patient
and disease states may change over time, and
that progressively smaller patient numbers over
time, as treatment is discontinued, may
influence efficacy and safety results.
Finally, it should also be noted that in the
LTE study reported in this analysis, the majority
of patients received a TDD of tofacitinib 10 mg
BID (n = 97), with two patients receiving
tofacitinib 5 mg BID; therefore, the efficacy and
safety data reported here for this study do not
correspond to the licensed dose of tofacitinib
(5 mg BID) in Australia, as well as that in most
countries where tofacitinib has received mar-
keting approval.
CONCLUSIONS
In phase III and LTE studies involving
Australian patients with RA, tofacitinib therapy
with background MTX or csDMARDs demon-
strated sustained efficacy for up to 60 months’
treatment, and was consistent with results
reported previously for the global population.
Although higher rates of AEs were observed
compared with the global population, tofacitinib
generally had a consistent safety profile with no
new safety signals for up to 69 months of
treatment.
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